Zepbound Cost Without Insurance 2026

Compare tirzepatide prices →

At a glance: Zepbound cost without insurance (2026)

Option	Estimated monthly cost (2026)	Notes
Zepbound vials or KwikPen — LillyDirect self-pay	$299–$449	2.5 mg $299 · 5 mg $399 · 7.5–15 mg $449 if refilled within 45 days ($499 at 7.5 mg, $699 at 10–15 mg otherwise)
Zepbound single-dose pen — self-pay	No self-pay price	The pen format most insurers cover; LillyDirect's self-pay prices apply to vials and the KwikPen
Zepbound — retail list price	~$1,086	Sticker price; few self-pay patients pay this
Zepbound — with commercial insurance + savings card	As low as $25	Only if plan covers Zepbound; commercial coverage only (not Medicare/Medicaid)
Zepbound — Medicare (GLP-1 Bridge)	$50 (July 1, 2026 – Dec 31, 2027)	KwikPen only, not vials or single-dose pens; eligible Part D members, prior authorization required
Wegovy (semaglutide) — self-pay	$349 ($199 intro)	NovoCare pen, 0.25–2.4 mg; $199 intro for new patients' first 2 fills, ending with 2026; different drug, different molecule
Compounded tirzepatide — telehealth providers we compared	~$135–$399	Lowest all-in price at 2.5 mg among providers we reviewed (Oct 2026); not FDA-approved; not therapeutically equivalent to Zepbound

Lilly and Novo prices as listed on Oct 13, 2026. Lilly's savings card terms and Novo's intro offer both expire at the end of 2026, and prices move often — verify current figures with the manufacturer, your pharmacy, and your insurer before making any decision. Sources: LillyDirect, NovoCare, and the Nouri GLP-1 telehealth pricing dataset (2026).

What does Zepbound cost without insurance in 2026?

Zepbound's retail list price is approximately $1,086 per month — the price at a standard pharmacy without any discount or insurance. Very few self-pay patients actually pay that amount. Eli Lilly sells Zepbound self-pay through LillyDirect so patients without insurance coverage can get it at a much lower price. Those self-pay vials and KwikPens are the realistic cash-pay option for most uninsured patients in 2026.

The key distinction is form factor: the self-pay prices apply to single-dose vials and the KwikPen (a multi-dose pen holding four weekly doses), not to the single-dose autoinjector pen typically dispensed at retail pharmacies, which has no self-pay price. The clinical dosing is the same; the delivery system differs. With a vial, patients draw the dose and self-inject, following their prescriber's instructions.

How LillyDirect Self-Pay vials work

Through LillyDirect, Lilly sells Zepbound vials and KwikPens in three price tiers based on dose (checked Oct 13, 2026):

• 2.5 mg: $299/month
• 5 mg: $399/month
• 7.5 mg, 10 mg, 12.5 mg, and 15 mg: $449/month if refilled within 45 days

The $449 ceiling for all higher doses is a notable feature, but it holds only when each refill comes within 45 days of the last. Otherwise the price is $499 at 7.5 mg and $699 at 10, 12.5 and 15 mg. Verify the current terms directly with LillyDirect before ordering.

These prices do not include any clinical or telehealth service fee. A prescribing provider must write a prescription; LillyDirect does not prescribe. Some telehealth platforms include the consultation fee in their quoted price; others charge separately.

Zepbound with insurance: the $25 savings card

If your commercial health insurance plan covers Zepbound, Lilly offers a savings card that can reduce your out-of-pocket copay to as little as $25/month, with savings capped at $100 a month and $1,300 a year; the current card terms end Dec 31, 2026. Important caveats:

• This applies to commercial insurance only — it is not available to Medicare or Medicaid patients.
• Coverage is plan-specific. Many commercial plans exclude weight-loss drugs entirely. Prior authorization is commonly required.
• Some pharmacy benefit managers have shifted Zepbound's formulary status in 2025–2026 — confirming your current formulary before starting is essential.

If your plan denies coverage, ask your prescriber about a prior authorization (PA) or a medical exception request. Prior authorization success rates vary; your prescriber's office can advise whether it is worth pursuing. For more detail, see Does Insurance Cover Wegovy & Zepbound? and How to Get a GLP-1 Covered by Insurance.

Does Medicare cover Zepbound?

Medicare coverage for Zepbound has historically been restricted. Starting in July 2026 and running to the end of 2027, the CMS Medicare GLP-1 Bridge lets eligible Part D members pay $50 a month once prior authorization is approved. For Zepbound it covers only the KwikPen, not vials or single-dose pens. Verify the current eligibility requirements and covered drug list directly on the CMS press releases page before counting on this program — details are subject to change.

Medicaid coverage varies by state. As of 2026, a minority of state Medicaid programs cover GLP-1s for weight management — typically tied to obesity-as-disease policies. Check your state's Medicaid formulary directly.

Zepbound vs Wegovy cost comparison

At self-pay rates, Zepbound and Wegovy are priced closer than most people expect:

• Zepbound vials or KwikPen (LillyDirect): $299–$449/month by dose
• Wegovy pen (NovoCare self-pay): $349/month at 0.25–2.4 mg after a $199 intro price on new patients' first 2 fills (offer ends with 2026); Wegovy HD 7.2 mg costs $399 and the Wegovy pill $149–$299, per NovoCare

These are different drugs with different active molecules. Zepbound contains tirzepatide; Wegovy contains semaglutide. The published clinical trials study these as separate branded medications. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) reported a mean 20.9% body weight reduction with tirzepatide over 72 weeks in adults with obesity. The STEP 1 trial (Wilding et al., NEJM 2021) reported a mean 14.9% body weight reduction with semaglutide. These are results from trials of those specific branded molecules — individual results vary, and these findings do not represent expected outcomes for any compounded product.

For a full side-by-side breakdown, see Tirzepatide vs Semaglutide and Compounded Tirzepatide vs Zepbound. For the full cost landscape across all GLP-1 options, see the GLP-1 cost guide (2026 pillar).

Is there a cheaper or generic version of Zepbound?

There is no FDA-approved generic Zepbound. Tirzepatide's patent protection means a generic is not expected in the near term.

The two main lower-cost routes are:

1. LillyDirect self-pay vials and KwikPens ($299–$449/month) — the lowest-price route for FDA-approved Zepbound.
2. Compounded tirzepatide (~$135–$399/month all-in at the starting dose, via the telehealth providers we compared) — prepared by state-licensed 503A compounding pharmacies and prescribed by licensed physicians. Compounded tirzepatide is not FDA-approved, not the same as Zepbound, and not therapeutically equivalent to Zepbound. The FDA notes specific considerations around compounded GLP-1 medications; patients should discuss these with their prescriber.

For a head-to-head cost breakdown of compounded versus brand-name options, see Compounded vs Brand GLP-1 Cost and the cheapest GLP-1 cost comparison.

Why does Zepbound cost so much?

Several factors drive Zepbound's price:

• No generic competition: tirzepatide is under patent protection; no lower-cost version is legally available from another manufacturer through standard pharmacy channels.
• High demand: GLP-1 medications for weight management have seen substantial demand growth, which affects supply chains and pricing leverage.
• U.S. drug pricing structure: the U.S. lacks centralized government price negotiation for most brand-name drugs outside of limited Medicare provisions. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) notes that prescription medications for obesity are an important and growing treatment category, but insurance coverage and affordability remain significant barriers.
• Coverage variability: inconsistent insurance coverage means many patients must pay self-pay rates even with insurance.

The self-pay vial program is Lilly's response to this affordability problem. For patients who cannot afford brand-name Zepbound even at vial rates, compounded tirzepatide from a licensed 503A pharmacy — prescribed by a U.S.-licensed physician — is the other legal path to lower-cost tirzepatide.

Is Zepbound cheaper than Mounjaro?

For cash-pay patients, yes. Mounjaro contains the same active ingredient — tirzepatide — but holds FDA approval for type 2 diabetes management rather than weight management. LillyDirect sells the Mounjaro single-dose pen self-pay for $499 a month at every dose, versus $299–$449 for Zepbound vials and KwikPens (checked Oct 13, 2026, LillyDirect Mounjaro); Mounjaro's list price is $1,112.16 per fill.

If you have insurance that covers Mounjaro (diabetes indication) but not Zepbound (weight management), your prescriber may be able to request a prior authorization for Zepbound coverage. This is a clinical conversation, not a guarantee. Do not switch between these medications without guidance from your prescriber.

Can I use FSA or HSA funds for Zepbound?

Possibly, with important caveats. Prescription medications for obesity treatment may be eligible for reimbursement from a flexible spending account (FSA) or health savings account (HSA) under IRC §213(d), which covers medical care expenses. Eligibility depends on your specific plan's rules, and some plan administrators require a letter of medical necessity (LMN). FSA/HSA funds are generally used for reimbursement (you pay out of pocket and submit for reimbursement) — not direct payment at the pharmacy in all cases.

Confirm eligibility and reimbursement process with your plan administrator and a qualified tax professional before relying on this. For a full breakdown of GLP-1 FSA/HSA eligibility, see Can You Use HSA/FSA for a GLP-1?

Where Nouri fits on tirzepatide cost

This site no longer runs a telehealth program, and it doesn’t write prescriptions or ship medication. To weigh the tirzepatide routes side by side, use our tirzepatide price table: Zepbound, Mounjaro and the compounded providers we’ve looked at, sorted by monthly cost and dated.

When comparing telehealth pricing, watch for "$99/month" or similar teaser rates that carry a separate $49–$79/month membership fee on top; compare all-in numbers. An older snapshot of provider self-pay rates sits in the June 2026 telehealth pricing dataset.

Not all applicants qualify; Zepbound eligibility usually starts at BMI 30 (27 with a weight-related condition), and the prescriber makes the call. Compounded tirzepatide is not FDA-approved and is not the same as, or therapeutically equivalent to, Zepbound or Mounjaro.

Compare published GLP-1 prices →

Related cost guides

• GLP-1 Cost 2026: Full Pricing Guide (pillar)
• Tirzepatide Cost Without Insurance
• Wegovy Cost Without Insurance
• Compounded Tirzepatide vs Zepbound: What's the Difference?
• Compounded vs Brand GLP-1 Cost
• Does Insurance Cover Wegovy & Zepbound?
• Cheapest GLP-1: Full Cost Comparison
• Can You Use HSA/FSA for a GLP-1?

Paying cash? Two companion guides: tirzepatide with no insurance walks through paying cash, and buy compounded tirzepatide walks through how the compounded route works — prescription, 503A pharmacy, and delivery.

Frequently asked questions

How much does Zepbound cost per month without insurance?

LillyDirect self-pay Zepbound vials and KwikPens are $299/month at 2.5 mg, $399 at 5 mg and $449 at 7.5–15 mg if refilled within 45 days ($499 at 7.5 mg and $699 at 10–15 mg otherwise), checked Oct 13, 2026. The single-dose pen has no self-pay price, and the ~$1,086 list price is rarely what people pay. Verify current pricing with LillyDirect before purchasing.

Is Zepbound cheaper than Wegovy?

At self-pay they are close: Zepbound vials and KwikPens run $299–$449/month through LillyDirect, and the Wegovy pen is $349/month through NovoCare after a $199 intro price on new patients’ first 2 fills (offer ends with 2026). They are different drugs: Zepbound is tirzepatide; Wegovy is semaglutide. Published trial data (SURMOUNT-1, STEP 1) are studies of those branded molecules, not of any compounded product; individual results vary.

How much are Zepbound vials through LillyDirect?

$299/month for 2.5 mg, $399 for 5 mg and $449 for 7.5–15 mg, the same as the KwikPen. The $449 price holds only if you refill within 45 days; otherwise 7.5 mg is $499 and 10–15 mg is $699 (checked Oct 13, 2026).

Why is Zepbound so expensive?

There is no generic tirzepatide, demand is high, and brand-name drug prices in the U.S. reflect a market without centralized negotiation for most medications. Lilly's self-pay vials ($299–$449/month) and savings cards (as low as $25/month for covered commercial patients) exist specifically to address the affordability gap. The NIDDK and other public-health bodies have noted insurance coverage gaps as a major access barrier for obesity medications.

Does insurance cover Zepbound for weight loss?

Coverage is inconsistent. Many commercial plans exclude weight-loss medications or require prior authorization. Some PBMs have moved Zepbound on or off formulary. Check your specific plan formulary and, if denied, ask your prescriber about a prior authorization or medical exception. For more detail, see Does Insurance Cover Wegovy & Zepbound?

Is Zepbound cheaper than Mounjaro?

For cash pay, yes. Zepbound vials and KwikPens are $299–$449/month through LillyDirect, while the Mounjaro single-dose pen, the same active ingredient (tirzepatide) approved for type 2 diabetes, is $499/month at every dose there (checked Oct 13, 2026). If your insurance covers only Mounjaro, ask your prescriber whether a prior authorization for Zepbound is appropriate.

Is there a generic version of Zepbound?

No. There is no FDA-approved generic Zepbound. Compounded tirzepatide is a separate category: it is prepared by licensed 503A compounding pharmacies and prescribed individually by licensed physicians. It is not FDA-approved and is not therapeutically equivalent to Zepbound. See the FDA's guidance on compounding for more context.

How much is Zepbound a month?

Without insurance: $299–$449/month through LillyDirect self-pay vials or KwikPens (depending on dose, checked Oct 13, 2026). With commercial insurance that covers it, a savings card can reduce the copay to as little as $25/month. The ~$1,086 list price is the retail sticker without any program or insurance; few patients pay it. On Medicare, the GLP-1 Bridge charges eligible Part D members $50/month for the Zepbound KwikPen through Dec 31, 2027 — verify current eligibility at CMS.gov.

Sources & references

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022;387:205–216. [Tier 1 — primary trial of tirzepatide molecule]
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med 2021;384:989–1002. [Tier 1 — primary trial of semaglutide molecule]
3. FDA. Human Drug Compounding. U.S. Food & Drug Administration. [Tier 1 — regulatory guidance on compounding]
4. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Prescription Medications to Treat Overweight & Obesity. [Tier 1 — NIH/NIDDK obesity medication overview]
5. FDA. Postmarket Drug Safety Information for Patients and Providers — GLP-1 Agonists. [Tier 1 — FDA postmarket safety context]
6. Zepbound self-pay vials and KwikPen — LillyDirect (Eli Lilly). Checked Oct 13, 2026. [Tier 3 — manufacturer price source; verify before purchasing]
7. Mounjaro self-pay single-dose pen — LillyDirect (Eli Lilly). Checked Oct 13, 2026. [Tier 3 — manufacturer price source]
8. Wegovy self-pay & savings — NovoCare (Novo Nordisk). Checked Oct 13, 2026. [Tier 3 — manufacturer price comparison source]
9. CMS. Medicare GLP-1 $50 monthly access (Bridge program). CMS.gov.; CMS Medicare GLP-1 Bridge page [Tier 1 — government program; verify current status]
10. GLP-1 Telehealth Pricing Dataset (June 2026). HuggingFace. [Telehealth market pricing snapshot]

Medically reviewed by Amber Patel, MD · Nouri Editorial Team · Review date: June 29, 2026. Nouri content is reviewed by a U.S.-licensed clinician and updated as pricing and guidance change.

We last looked up Lilly’s and Novo’s self-pay prices on Oct 13, 2026 (coverage notes are older, from June 2026), and all of it changes often — verify current figures with the manufacturer, your pharmacy, your insurer, and (for HSA/FSA or tax questions) a qualified tax professional before making decisions. This content is general information only; it is not medical, financial, or tax advice and does not constitute a provider-patient relationship. Ozempic®, Wegovy®, and Rybelsus® are registered trademarks of Novo Nordisk A/S; Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. Nouri is not affiliated with, endorsed by, or sponsored by these companies. Compounded tirzepatide is not FDA-approved and is not the same as, or therapeutically equivalent to, Zepbound® or Mounjaro®. Compounded medications are prescribed only when a licensed prescriber decides treatment is clinically appropriate. This site publishes information only and sells no medication. Individual results vary.